123 results
424B5
CNTA
Centessa Pharmaceuticals plc
13 Sep 24
Prospectus supplement for primary offering
4:02pm
for that purpose is required, other than in the United States. The distribution of this prospectus supplement and the accompanying prospectus … to the ADSs may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which
8-K
EX-1.1
CNTA
Centessa Pharmaceuticals plc
13 Sep 24
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
4:00pm
the effectiveness of the Registration Statement or the ADS Registration Statement is in effect, and no proceedings for such purpose or pursuant to Section 8A … thereof or any other law or regulation the purpose of which is to protect the privacy of individuals or prescribers;
(iv) the Patient Protection
8-K
EX-5.1
CNTA
Centessa Pharmaceuticals plc
13 Sep 24
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
4:00pm
”.
INTRODUCTION
Purpose
In connection with the preparation and filing of a prospectus supplement dated 12 September 2024 (the “Prospectus Supplement … Pharmaceuticals plc
13 September 2024
Page 2
Legal review
For the purpose of issuing this letter, we have examined such questions of law as we have
424B5
CNTA
Centessa Pharmaceuticals plc
11 Sep 24
Prospectus supplement for primary offering
4:40pm
or the accompanying prospectus in any jurisdiction where action for that purpose is required, other than in the United States. The distribution of this prospectus … or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed
S-3ASR
CNTA
Centessa Pharmaceuticals plc
11 Sep 24
Automatic shelf registration
4:01pm
available for the purpose of making a distribution are its accumulated, realized profits, so far as not previously utilized by distribution … of the company or the proceeds of a fresh issue of shares made for the purpose of financing the purchase, subject to complying with procedural
S-3ASR
EX-4.6
47c0m aj82f08bt93d9
11 Sep 24
Automatic shelf registration
4:01pm
S-3ASR
EX-4.4
xujq5mr2l o0
11 Sep 24
Automatic shelf registration
4:01pm
S-3ASR
EX-5.1
mweti1q5i5b7wm8uxno
11 Sep 24
Automatic shelf registration
4:01pm
8-K
EX-99.2
me3xlj8y63k
10 Sep 24
Regulation FD Disclosure
7:08am
DEFA14A
hfqqjanvjrh05
20 May 24
Additional proxy soliciting materials
8:48pm
PRE 14A
lyt80wbm
26 Apr 24
Preliminary proxy
4:36pm
424B5
m52a63jgl
24 Apr 24
Prospectus supplement for primary offering
8:53pm
8-K
EX-5.1
xcimf4ng32hv2hnaj198
24 Apr 24
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
9:26am
8-K
EX-1.1
3u7aqbrp1hw 5tad2z
24 Apr 24
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
9:26am
424B5
shb2qd 36ytyh2
23 Apr 24
Prospectus supplement for primary offering
5:16pm